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On the basis of mouse I-Ab-binding motifs, two sequences of the murine apolipoprotein 
B-100 (mApoB-100), mApoB-1003501–3515 (designated P3) and mApoB-100978–992 
(designated P6), were found to be immunogenic. In this report, we show that P6 is also 
atherogenic. Immunization of Apoe−/− mice fed a high-fat diet (HFD) with P6 resulted 
in enhanced development of aortic atheroma as compared to control mice immunized 
with an irrelevant peptide MOG35–55 or with complete Freund’s adjuvant alone. Adoptive 
transfer of lymph node cells from P6-immunized donor mice to recipients fed an 
HFD caused exacerbated aortic atheromas, correlating P6-primed cells with disease 
development. Finally, P6-specific T cell clones were generated and adoptive transfer 
of T cell clones into recipients fed an HFD led to significant increase in aortic plaque 
coverage when compared to control animals receiving a MOG35–55-specific T cell line. 
Recipient mice not fed an HFD, however, did not exhibit such enhancement, indicating 
that an inflammatory environment facilitated the atherogenic activity of P6-specific T cells. 
That P6 is identical to or cross-reacts with a naturally processed peptide of ApoB-100 
is evidenced by the ability of P6 to stimulate the proliferation of T cells in the lymph node 
of mice primed by full-length human ApoB-100. By identifying an atherogenic T cell 
epitope of ApoB-100 and establishing specific T cell clones, our studies open up new 
and hitherto unavailable avenues to study the nature of atherogenic T cells and their 
functions in the atherosclerotic disease process.
Keywords: T-cell, atherosclerosis, clones, adoptive transfer, peptides, epitopes
Abbreviations: HFD, high-fat diet; HEL, hen egg lysozyme; Ldlr−/−, low-density lipoprotein receptor deficient; PPD, purified 
protein derivative.
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inTrODUcTiOn
Atherosclerosis is a chronic inflammatory condition of medium 
and large arteries, affecting more than 81 million people in the 
United States and accounting for 1 in 3 deaths of the resulting 
cardiovascular disease (1). Traditionally, atherosclerosis is 
believed to initiate from injuries or dysfunction of endothelial 
cells lining the inner wall of the vessels (2), thus allowing 
unabsorbed low-density lipoproteins (LDL) to diffuse into the 
intima and forming fatty streaks (3). Subsequently, activated 
macrophages upregulate their endocytic pattern-recognition 
receptors (4) and internalize oxidized LDL (oxLDL), which gives 
them their foam-cell appearance (5). These macrophages release 
inflammatory cytokines and recruit inflammatory immune 
cells to the site. Continuous influx of mononuclear cells and 
inefficient clearance of dead cells (efferocytosis) eventually give 
rise to the formation of atheromatous plaques with a central 
necrotic lipid core and a fibrous cap (6). Because oxLDL appears 
to act as an initiator of the disease process (3), current therapies 
emphasize elevated plasma LDL cholesterol as a major risk factor 
and statins are prescribed to lower cholesterol levels. However, 
lowering cholesterol to below 100 or even 70 mg/dl only resulted 
in a decrease in the number of major adverse cardiovascular 
events by 30–35% (7). Incomplete prevention suggests that fac-
tors other than LDL cholesterol are contributing to the overall 
atherosclerotic development.
In the last two decades, through the work of Hansson and 
co-workers (8, 9), it is well established that the immune system, 
both innate and adaptive, contributes to the progression of the 
disease (10). First, anti-oxLDL antibodies circulate in patients 
with atherosclerosis (11). Mice immunized with oxLDL also 
develop circulating antibodies to the immunogen (12). Second, 
immune cells are notably found in abundance in human and 
murine atherosclerotic plaques throughout the stages of disease 
development (13). Inflammatory T cells and the inflammatory 
cytokine, interferon-gamma (IFNγ), are found to be determin-
ing factors in the development of atherosclerotic plaques. This 
is supported by the observation that Apoe−/− mice deficient 
in IFNγ or IFNγ receptors exhibit significant reduction in 
atherosclerotic lesion size compared to controls (14). On the 
other hand, injection of exogenous IFNγ to Apoe−/− mice fed a 
high-fat diet (HFD) result in a twofold increase in lesion size 
(15). Apoe−/− mice have a defect in the Apoe gene (16), which is 
responsible for transport of chylomicrons and very low-density 
lipoprotein (VLDL) from the blood stream. Apoe−/− mice on 
chow diet respond to this mutation with high total cholesterol 
levels >500  mg/dl, mostly in the VLDL and chylomicron 
remnant fractions. These levels are even more pronounced on 
an HFD, whereby they develop significant atherosclerosis not 
seen in an otherwise wild-type mouse. In addition, deficiency 
of transcription factors or cytokines such as T-bet, IL-12, and 
IL18 which promote Th1 differentiation and expression of IFNγ 
genes are shown to reduce atherosclerosis in Apoe−/− mice (17). 
The role of Th17 cells in atherosclerosis, however, has been 
controversial, as both beneficial and detrimental effects have 
been reported (18, 19). Evidence that regulatory T cells (Tregs) 
modulate the disease comes from adoptive transfer studies of 
CD4+CD25+ Tregs that resulted in reduction of atherosclerosis 
in Apoe−/− mice (20). Furthermore, a recent human study 
showed that the number of circulating Tregs in peripheral blood 
was inversely associated with the development of myocardial 
infarction and for coronary events in general (21). Thus, a gener-
ally projected model is that Th1 cells produce inflammatory 
cytokines which may be counteracted by Tregs through the 
production of transforming growth factor beta (22–24). This 
model, though tenable, was deduced from the observed physical 
presence of certain T cell subpopulations and their cytokines in 
the lesions and from gene knockout data. It provides a frame-
work in which many fundamental mechanistic questions are still 
unresolved. For example, it is unclear how and why T cells are 
triggered to become atherogenic and what systemic roles they 
play in the processes of atheroma formation and progression. 
In addition, while it is assumed that atherogenic T cells belong 
to the Th1 and Th17 subclasses, isolation of a homogenous 
population of such atherogenic T cells has not been success-
ful. We contend that these questions require new strategies as 
well as novel experimental approaches to fully understand the 
mechanisms of T cell atherogenicity. In this respect, we adopt 
a basic immunological approach and aim to unravel the events 
that initiate the T cell atherogenic response. Since T cells are 
triggered to respond mostly through their antigen receptors, 
we reason that identification of the atherogenic peptides would 
provide a direct pathway leading to isolation and characteriza-
tion of the atherogenic T cells themselves.
We previously described identification of two immuno-
genic T cell epitopes, mApoB-1003501–3515 (designated P3) and 
mApoB-100978–992 (designated P6), derived from the apolipo-
protein B-100 (ApoB-100) of LDL. Immunization of C57Bl/6, 
Apoe−/−, or Ldlr−/− mice with P3 or P6 emulsified in complete 
Freund’s adjuvant (CFA) induced strong peptide-specific T 
cell proliferative responses in  vitro (25). In this report, we 
provide further evidence that P6 is an atherogenic epitope. 
Immunization of Apoe−/− mice with P6 emulsified in CFA 
resulted in a significant increase of aortic atherosclerotic 
lesions in mice fed a high-fat Western diet. More importantly, 
exacerbation of aortic atheroma development can be adoptively 
transferred to unprimed recipients with P6-primed T cells as 
well as P6-specific T cell clones. This new experimental model 
allows us, for the first time, to obtain homogeneous populations 
of antigen-specific atherogenic T cells for analysis. It also opens 
up new possibilities to study the nature of atherogenic T cell 
populations and their functional significance in the disease 
process.
aniMals anD MeThODs
Mice
Female C57BL/6 mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME, USA). Male and female Apoe−/− 
mice on the C57BL/6 background were bred in our colonies. In 
some experiments, mice were fed a HFD starting at 8 weeks of age. 
All experimental procedures involving live animals received prior 
approval from Institutional Animal Care and Use Committee of 
Wayne State University.
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antigens and Peptides
All murine ApoB-100 (mApoB-100) peptides and MOG35–55 pep-
tides were synthesized by Genemed Synthesis Inc (San Antonio, 
TX, USA). Peptides were dissolved in phosphate-buffered saline 
(PBS) and adjusted to 2  mg/ml. Human apolipoprotein B-100 
(hApoB-100) full-length protein was purchased from Abcam 
(Cambridge, MA, USA) and was dialyzed extensively against PBS 
before use.
identification of mapoB-100 iab-Binding 
Motifs
Based on analysis of the alignment of 64 peptides that bound 
to IAb, Liu et  al. (26) delineated a set of possible residues that 
most frequently serve as anchor residues for IAb binding. In this 
analysis, four major histocompatibility complex (MHC) contact 
positions were defined (peptide positions 1, 4, 6, and 9) and the 
three most common amino acids used at each site were listed 
(position 1, A, F, and Y; position 4, S, A, and P; position 6, V, 
P, and A; position 9, S, V, and A). This analysis also provided 
potential T cell interacting residues in positions 2, 3, 5, and 8. We 
arbitrarily deemed any 9-mer peptide with three MHC contact 
residues to be potential I-Ab-binding peptides. We developed a 
strategy to scan for such binding motifs along the 4505 amino 
acid sequence of ApoB-100. We first searched for any of the three 
amino acids found in MHC contact position 1 (A, F, or Y) and 
designated this amino acid position 1 of our potential 9-mer. We 
then determined the amino acids corresponding to positions 
4, 6, and 9 downstream of the first position. If any two of the 
remaining three positions also had an amino acid used frequently 
in I-Ab-binding peptides, we designated the 9-mer as a candidate 
for further characterization. Similarly, we searched the ApoB-100 
sequence for amino acids corresponding to those used frequently 
in position 4. We then searched upstream and downstream from 
this residue for amino acids corresponding to positions 1, 6, 
and 9. This strategy defined another subset of potential 9-mers. 
We repeated this search starting with amino acids often used in 
positions 6 and 9 of the I-Ab-binding motif. Two more subsets 
of potential 9-mers were thus defined. In all, 18 potential I-Ab-
binding 9-mers were designated. Given their primary sequence, 
six of these were determined to have adequate water solubility to 
be used in experiments.
immunization of Mice
For immunization, protein antigens and peptides at 2  mg/ml 
were emulsified with an equal volume of CFA supplemented 
with 1  mg/ml of Mycobacterium tuberculosis H37Ra (Difco 
Laboratories, Detroit, MI, USA). Then, 0.05 ml of the emulsion 
was given s.c. at each of four sites in the flanks draining the ingui-
nal and axillary lymph nodes (27). Mice were used 10–14 days 
after immunization.
cell cultures and adoptive Transfer
For bulk cultures (27), the inguinal and axillary lymph nodes 
were removed aseptically 10 days after immunization and teased 
into single cell suspensions. Cells were washed twice and put 
into culture at 4 × 106/ml in RPMI supplemented with 10% fetal 
calf serum, 2 mM l-glutamine, 1 mM MEM sodium pyruvate, 
0.1 mM MEM non-essential amino acids, 100 U/ml penicillin, 
100 µg/ml streptomycin, 10 mM HEPES buffer, and 5 × l0−5 M 
2-ME together with the specific antigens. Cells were cultured in 
2-ml volume in 24-well plates at 37°C with 5% CO2/air for 4 or 
5 days as specified.
For adoptive transfer, cells were harvested, washed, and resus-
pended in PBS to appropriate volumes. Each recipient received 
0.2 ml of a cell suspension containing 5 × 107 viable cells through 
the tail veins.
T cell Proliferative assay (28)
Draining lymph nodes were harvested and teased into single cell 
suspensions 10–14 days after immunization. A total of 3 × 105 
viable cells per microtiter well were cultured with 50–100  µg/
ml of the peptides for 4  days. In some cases, purified protein 
derivative (PPD) served as a positive control, and a peptide of 
MOG or OVA served as negative controls. Sixteen hours before 
harvesting, 1 μCi of tritiated thymidine was added to each well. 
Cells were harvested and incorporation of 3H was determined in a 
scintillation counter. Results are expressed as stimulation indexes 
(SIs) using the following formula:
 SI
counts per minute cpm  experimental
cpm medium control
=
−( ( )
)
.
cpm medium control
 
atherosclerosis Quantification
The procedures used were adopted from the Eitzman Lab (29). 
Apoe−/− mice were perfused with saline at physiological pressure 
and then fixed using formalin with a 25-gauge needle inserted into 
the left ventricle at a rate of 1 ml/min. The arterial tree was then 
meticulously dissected and placed in 70% ethanol. After staining 
with Oil Red O, the aorta was pinned on wax. Pinned aortic tissue 
was imaged using a SPOT camera (Spot Imaging; Sterling Heights, 
MI, USA) mounted to a Leica M165FC Stereomicroscope (Leica 
Biosystems; Nussloch, Germany). Identical settings were used for 
all samples. The surface area occupied by atherosclerotic plaques 
was quantified at the aortic arch and major branches with Image-
Pro Plus software (Media Cybernetics, Bethesda, MD, USA). The 
lesion area was expressed as a percentage of total surface area 
examined.
T cell cloning
T cells were cloned by the limiting dilution method of MacDonald 
et al. (30, 31). Briefly, lymph node cells from Apoe−/− mice primed 
10–12 days previously with P6/CFA were placed in bulk cultures 
in 2-ml volumes with P6 at 25  µg/ml in 24-well plates. After 
1 week in culture, half of the media in each well was replaced 
with fresh media plus 25 U/ml of mouse recombinant IL-2 with-
out fresh antigen or antigen-presenting cells. After 1 week, cells 
were harvested, washed, and resuspended to concentrations 
containing 30,000, 3,000, 300, and 30  cells/well, respectively. 
Then, 0.1 ml of each cell concentration was dispensed to each 
well of a 96-round-bottom-well plate. Total cell concentration 
in each well was brought up to 3 × 105 by addition of appropri-
ate numbers of irradiated (3,000 rad) syngeneic spleen cells. P6 
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was used at 50 µg/ml and mouse recombinant IL-2 at 25 U/ml. 
Signs of T cell growth in the round-bottomed wells as a ring 
of elongated cells surrounding the cell pellet were determined 
by visual inspection of individual wells on an inverted micro-
scope. Plates with less than 37% positive wells with growth were 
considered clonal according to the Poisson distribution theory 
(31). Wells with positive growth went through 2-week cycles of 
stimulation and resting as described above for bulk cultures. 
Positive wells were expanded to 24-well plates and then T15 
culture flasks. Testing of antigen specificity was performed with 
T cell proliferative assays.
resUlTs
immunogenic T cell epitopes of  
apo-B100 serve as a lead to identify 
atherogenic T cells
Immune T cells are triggered most commonly through the 
T cell receptor (TCR) by binding of a ligand that is composed of 
an antigenic peptide embedded within an MHC molecule. It is 
thus reasonable to expect that elucidation of a defined peptide 
that is atherogenic would provide the means for identifica-
tion and isolation of atherogenic T cell populations useful for 
functional studies under controlled conditions. To this end, 
we made use of the concept of the H-2 IAb-binding motifs 
described by Liu et al. (26) to search for IAb-binding peptide 
sequences of mApoB-100, an apolipoprotein molecule found 
on the surface of the LDL particle (32). Each LDL particle has 
a single copy of ApoB-100 (33). We identified 18 sequences 
that fit the IAb-binding motifs, 6 of which were synthesized 
for further study. These six 15-mer-peptides were designated 
peptides 1–6 (25). Apoe−/− mice were immunized with each 
peptide followed by an extensive analysis of the responses to 
the respective peptide and to each other as measured in a 
T cell proliferative assay (28). PPD and concanavalin A (Con 
A) were used as positive controls. Lymph node cells of mice 
immunized with P3 (mApoB-1003501–3515) or P6 (mApoB-
100978–992) mounted strong T cell proliferative responses to their 
respective peptides (Table 1). No apparent cross-reactivity was 
detected between the two peptides. Titration of antigen doses 
in B6 and Apoe−/− mice to P3 and P6 also showed a dose 
dependency of the T cell proliferative responses (Figure  1). 
By contrast, P1, P2, P4, and P5 were not immunogenic and 
did not elicit any positive T cell responses in immunized mice. 
These results were confirmed by physical binding affinity data 
in which P3 and P6 were shown to have high-binding affinities 
to I-Ab, while the other four peptides had low-binding affini-
ties (34). The observed responses to ApoB-100 peptides were 
not confined to Apoe−/− mice only. C57BL/6 and Ldlr−/− mice 
immunized with these peptides had similar response patterns 
(25). In addition, the proliferative responses induced by P3 
and P6 immunization were largely due to CD4+ T cells. As 
shown in Table 2, P3- or P6-primed ApoE−/− lymph node cells 
positively selected for CD4+ or CD8+ T cells by antibody-
coated microbead columns (Miltenyi Biotec) were assessed 
in T cell proliferative assays. The bulk of the lymph node 
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FigUre 1 | Titration curves of T cell proliferative responses to peptide3 (apoB-100p3501–3516) and peptide6 (apoB-100p978–993). C57BL/6 or Apoe−/− 
mice were immunized with P3 or P6. Ten days later, draining lymph nodes were isolated and teased into single cell suspension. A total of 2 × 105 lymph node cells 
were cultured with no or titrating concentrations of their respective priming peptides for 5 days. Sixteen hours before the termination of the cultures, 1 μCi of tritiated 
thymidine was added to each well. Cultures were harvested in an automatic cell harvester, and the incorporation of 3H was counted in a liquid scintillation counter.
TaBle 2 | cD4+ and cD8+ T cell subsets responding to peptides 3 and 6.
In vitro proliferative responses (stimulation index)a
immunizing ag (200 μg/mouse) cell populations  
(2 × 105 cells)
Medium (cpm) Peptide3 (100 µg/ml) Peptide6 (100 µg/ml) MOg35–55 (100 µg/ml)
Peptide 3 Unseparated 2,387 18.0 ± 4.6 0.0 ± 0.5 −1.0 ± 0.2
CD4+ 1,911 24.0 ± 6.0 0.0 ± 0.3 −1.0 ± 0.1
CD8+ 1,764 −1.0 ± 0.0 −0.1 ± 0.0 −1.0 ± 0.3
Peptide 6 Unseparated 2,005 0.0 ± 0.4 9.0 ± 0.8 −1.0 ± 0.2
CD4+ 1,793 0.0 ± 0.4 22.0 ± 3.2 −1.0 ± 0.1
CD8+ 1,862 0.0 ± 1.9 0.0 ± 0.3 2.0 ± 0.5
Apoe−/− mice were immunized with P3 or P6 as described in Table 1. Ten days later, draining lymph node cells from both groups were isolated. The cells were passed through anti-
CD4 microbead MAC columns and anti-CD8 columns from Miltenyi Biotech to positively isolate CD4+ and CD8+ T cells, respectively. Purified cells, together with unseparated cells 
were assayed for T cell proliferative responses. All cultures were established in triplicates, and the results were expressed as the mean number of counts per minute ± SEM.
aSIs are calculated by the following formula: counts per minutes (CPM) experimental counts per minute (C− PM) medium background
counts per minute (CPM) medium background
.
Bold font indicates the important data.
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results indicated that P3 and P6 sequences are immunogenic 
and are able to invoke an immune response through activation 
of CD4+ T cells.
cell proliferative responses were confined to the CD4+ T cell 
population for both peptides, while the CD8+ T cell population 
did not appear to contribute to the overall responses. These 
FigUre 2 | experimental scheme for immunization of ApoE−/− mice with apolipoprotein B-100 peptides.
6
Shaw et al. Self-Peptide Exacerbates Murine Atherosclerosis
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 95
Only P6 (mapoB-100978–992) is Both 
immunogenic and atherogenic
With the first identification of two unique T cell epitopes of 
ApoB-100, we next determined whether these epitopes were 
also atherogenic. The experimental design depicted in Figure 2 
was followed. In this experiment, all groups of mice were fed a 
HFD for the 10-week duration. The mice were immunized after 
5 weeks of feeding. MOG35–55, a peptide of myelin oligodendro-
cyte glycoprotein, served as an irrelevant peptide control. Since 
all peptide antigens were emulsified in CFA and CFA itself may 
be inflammatory, a second control with saline emulsified in CFA 
was used. At the end of 10  weeks, mice were sacrificed, and 
the aortic roots and aortic arches were isolated following the 
methods used by Eitzman and co-workers (29). The extent of 
plaque coverage was assessed via en face staining of the aortic 
samples with Oil Red O. Figure 3 shows that mice immunized 
with saline emulsified in CFA and fed an HFD provided a baseline 
level of plaque area coverage for comparison with other groups. 
Mice immunized with MOG35–55 emulsified in CFA had similar 
background plaque area level, indicating that this irrelevant 
peptide had no effect on atherosclerotic plaque burden as a result 
of the HFD. In contrast, mice immunized with P6 emulsified 
in CFA and with an HFD had greatly increased total area of 
plaque coverage, thus demonstrating the atherogenic nature 
of P6. This increase in plaque coverage was highly significant 
when compared to saline–CFA and MOG35–55–CFA controls. 
Surprisingly, mice immunized with P3, under similar conditions, 
did not show such an enhancement of disease. We conclude that 
while some ApoB-100 peptides may be immunogenic, they are 
not necessarily also atherogenic. The basis of the differences in 
atherogenicity between P3 and P6 is not known at this point 
but is under investigation. Nevertheless, the fact that P6 peptides 
are atherogenic offers a novel experimental model to study the 
mechanisms of T cell epitope-specific atherogenic development 
from an immunological perspective.
adoptive Transfer of P6-Primed lymph 
node T cells exacerbates atherosclerosis
The previous experiments established an association between 
immunization with P6 and exacerbation of atherosclerotic 
development. To demonstrate direct causal effects of P6 prim-
ing and disease exacerbation, we performed adoptive transfer 
of P6-primed lymph node cells into unprimed recipients and 
assessed the effects on development of atherosclerotic plaques. 
Apoe−/− mice were immunized with P6 or MOG35–55 peptides 
emulsified in CFA. Ten days later, draining lymph node cells from 
each group were harvested and cultured in bulk with the respec-
tive antigens for 5 days. At the end of the culture period, 5 × 107 
viable cells were adoptively transferred through the tail vein 
into 12-week-old ApoE−/− recipients which had been fed a HFD 
for 5 weeks prior to receiving cell transfer and were continued 
to be fed the HFD for the next 5 weeks post cell transfer. Mice 
fed a HFD and received P6-primed lymph node cells exhibited 
enhanced atherosclerotic plaque burden when compared to those 
in control mice receiving the irrelevant antigen MOG35–55-primed 
lymph node cells (Figure 4). These data unequivocally demon-
strate a causal role of P6-specific T cells in aggravating plaque 
formation in atherosclerosis.
P6-specific T cells exacerbate but Do 
not initiate atherosclerosis Development
To reveal whether the pre-feeding with HFD was necessary to 
manifest the enhancement effects of P6 immunization, we also 
adoptively transferred P6-primed and MOG-primed lymph node 
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FigUre 3 | immunization with P6 enhanced development of 
atherosclerosis in Western diet-fed Apoe−/− mice. Apoe−/− mice were 
fed a high-fat diet for 5 weeks. Groups of mice were then immunized with P3, 
P6, MOG35–55, or saline emulsified with complete Freund’s adjuvant by 
procedures described in Table 1. Two weeks later, mice were given a boost 
with 100 μg of the same priming peptide subcutaneously at the back. Three 
weeks later, aortas were isolated according to the procedures developed in 
the Eitzman Lab (29). After staining with Oil Red O, the aorta was pinned on 
wax. Pinned aortic tissue was imaged, and the surface area occupied by 
atherosclerotic plaques was quantified at the aortic arch and major branches 
with Image-Pro Plus software. The lesion area was expressed as a 
percentage of total surface area examined. (a) Representative aortas from 
each group. (B) Dot plot of data.
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FigUre 4 | high-fat diet feeding was necessary for enhanced 
atherosclerotic lesions. Apoe−/− mice were fed a high-fat diet or regular 
mouse chow. Five weeks later, the two groups of mice received 5 × 107 
lymph node cells from donor  Apoe−/− mice immunized with either P6 or 
MOG35–55 peptides. The primed donor lymph node cells were cultured with 
their respective antigens for 5 days before adoptive transfer. The HFD-P6 and 
HFD-MOG groups continued to be fed a HFD for another 5 weeks. The 
chow-P6 and chow-MOG groups were fed regular mouse chow. After 5 
weeks, mouse aortas were isolated and stained with Oil Red O, and the 
areas of atherosclerotic plaques were quantified. The lesion area was 
expressed as a percentage of total surface area examined.
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cells into two separate groups of 12-week-old Apoe−/− recipients 
which were fed the regular mouse chow throughout rather than 
given the HFD. As demonstrated in Figure 4, Apoe−/− mice fed 
regular chow and receiving either MOG-primed or P6-primed 
lymph node cells did not exhibit any aortic lesions, suggesting 
that an inflammatory environment created by feeding HFD is 
a critical factor for the atherosclerosis-promoting function of 
P6-specific T cells. Relevant to this conjecture, we have demon-
strated in a separate study (Wolf et al., submitted for publication) 
that feeding Apoe−/− mice an HFD led to rapid loss of P6/IAb 
tetramer+Foxp3+ Tregs.
P6 is a naturally Processed Peptide 
of apoB-100
We further determined if P6 can mimic a naturally processed 
physiologic peptide of the native ApoB-100 molecule. We 
immunized Apoe−/− mice with the native ApoB-100 molecule 
and tested in vitro if P6 could stimulate a proliferative response 
in ApoB-100-primed lymph node cells. As it is not realistically 
possible to extract sufficient amount of mouse ApoB-100 protein 
from mouse sera for testing, we purchased full-length hApoB-
100 protein from a commercial source (Abcam, Cambridge, MA, 
USA). The P6 peptide sequence N′-TGAYSNASSTESASY-C′ 
(mApoB-100978–992) of mouse ApoB-100 is 100% homologous to 
its counterpart in hApoB-100. Table 3 shows that lymph node 
cells from mice immunized with full-length hApoB-100 molecule 
responded to stimulation in vitro with not only the priming anti-
gen hApoB-100, but also with P6. Similarly, lymph node cells from 
mice immunized with P6 responded to the priming antigen P6 
as well as the hApoB-100 full-length protein. Since hApoB-100-
primed T cells recognized and responded to P6 stimulation, this 
is indicative that a peptide identical to or cross-reactive with P6 
was generated in the antigen processing of hApoB-100. Indeed, in 
support of this conjecture, in a separate collaborative study, Wolf 
et al. (submitted for publication) showed that P6/IAb tetramer+ 
P6-specific T cells were present in normal Apoe−/− mice.
P6-specific T cells clones exacerbate 
atherosclerosis in recipient Mice
To gain further understanding of the nature of the atherogenic 
T cells, we generated P6-specific T cell clones by limiting 
dilution (30, 31). Nine P6-specific T cell clones were initially 
derived and validated by T cell proliferative assay. Many of 
these clones had SIs of 80–150 (Table  4). Clones P6-11 was 
uniformly IFNγ producing as analyzed by flow cytometry 
(Table  4), which was conceivable as the clones were origi-
nally derived from mice immunized with CFA, which is TH1 
polarizing. All T cell clones were recloned to assure clonality, 
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FigUre 5 | P6-specific T cell clone adoptively transferred 
exacerbation of atherosclerotic development T cell clones were 
derived by the limiting dilution technique (31). Apoe−/− mice were fed a 
high-fat diet for 5 weeks. The mice were divided into two groups. A total of 
2 × 107 T cell clone specific for P6 or T cell line specific for MOG35–55 were 
adoptively transferred into each group. Five weeks later, the mice were 
analyzed for the extent of plaque lesions via en face staining of the aortic 
samples with Oil Red O. *p = 0.001.
TaBle 4 | Proliferative responses of P6-specific T cell clones.
In vitro proliferative responses % of cloned T cells secreting interferon 
gamma (iFnγ) assessed by flow 
cytometry intracellular staining
clone #  
(5 × 104 cells)
Medium 
cPM
Peptide 6 Purified protein  
derivative (PPD)
T cell clones stimulated with
cPM stimulation  
index (si)
cPM si PPD Peptide 6
P6-6 17 47 1.8
P6-9 27 289 2.8
P6-11 27 1,562 56.2 164 1.1 3.31 80.25
P6-12 27 2,231 80.8 314 10.6
P6-13 24 964 39.2
P6-14 26 1,205 45.3
P6-15 15 426 26.8
P6-24 14 2,090 148.3
P6-25 37 65 0.8
5 × 104 P6-specific T cell clones were cultured with or without 50 µg/ml of P6 together with 5 × 104 irradiated spleen cells as APC in 96-well culture plates. Some cultures 
contained 20 µg/ml of PPD as negative control. Sixteen hours before termination of cultures, 1 μCi of tritiated thymidine (3H) was added to each well. The results were 
expressed as mean counts per minute and as stimulation indexes. The clonality of clone P6-11 was assessed by intracellular staining for IFNγ. P6-11 was stimulated in culture 
for 48 h with either PPD or Peptide 6 and 106 irradiated spleen cells as antigen-presenting cells, some of which might have survived the 48-h culture and appeared as non-
IFNγ-secreting cells.
Bold font indicates the important data.
TaBle 3 | T cell proliferative responses of human apolipoprotein B-100 (hapoB-100)-primed lymph node cells.
In vitro proliferative responses [stimulation index (si)]a
immunizing ag (100 µg/mouse) Medium (cpm) hapoB-100 (50 µg/ml) P6 (50 µg/ml) Purified protein derivative (PPD) 
(20 µg/ml)
OVa (100 µg/ml)
hApoB-100 3,354 3.30 4.03 8.35 0.04
P6 3,567 2.86 7.25 8.87 0.15
Groups of Apoe−/− mice were immunized with hApoB-100 native molecule and P6 following the procedures described in Table 1. T cell proliferative assay was performed 10 days 
later. PPD was used as positive controls and OVA as negative controls. All cultures were established in triplicates.
aSIs are calculated by the following formula: counts per minutes (CPM) experimental counts per minute (C− PM)medium background
counts per minute (CPM) medium background
.
8
Shaw et al. Self-Peptide Exacerbates Murine Atherosclerosis
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 95
aliquoted, stored frozen, and subsequently tested for antigen 
specificity and atherogenicity.
To assure that the cloned T cells maintained their atherogenic-
ity, we adoptively transferred through the tail vein 2 × 106 P6-11 
T cell clones or 2 ×  107 MOG35–55-primed cell line, which had 
been maintained for several cycles (not cloned), into 12-week-
old Apoe−/− mice which had been fed a HFD for 5 weeks prior 
to receiving the cells. After additional 5  weeks of feeding post 
cell transfer, the extent of plaque lesions was assessed via en face 
staining of the aortic samples with Oil Red O. Mice that received 
P6-11 cloned cells had greatly enhanced atherosclerotic develop-
ment as compared to mice that received the MOG35–55-primed 
control cells (Figure 5). These results indicate our ability to obtain 
a homogenous population of atherogenic T cells. These T cell 
clones offer a new opportunity to further understand the role of 
T cells in the development of atherosclerotic lesions.
DiscUssiOn
This report describes a new strategic approach establishing 
an experimental system to study T cell atherogencity. First, 
we identify a self-peptide mApoB-100978–992 (designated P6) 
of mouse ApoB-100, which is a T cell epitope and is clearly 
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involved in the development of atherosclerotic lesions. Second, 
T cells specific for this peptide have been cloned and are shown 
to adoptively transfer exacerbation of plaque development in 
recipients. It is also interesting to observe that while these T 
cell clones exacerbate the disease, they do not seem to initiate 
the development of atherosclerosis. To our knowledge, this is 
the first study that identifies a T cell epitope and generates 
epitope-specific T cell clones which are atherogenic. A recent 
report published in 2012 by Wick’s group (35) described the 
proliferative responses of T cells generated from human ath-
erosclerotic lesions by stimulation with peptides of heat shock 
protein 60 (HSP60). These proliferative T cells presumably were 
atherogenic because they were generated from atherosclerotic 
lesions, but this presumption was not directly demonstrated. 
A similar study with T cell clones derived from human ath-
erosclerotic plaques were reported by Benagiano et  al. (36) 
in 2005. These T cell clones mounted strong proliferative 
responses to hHSP60 peptides, but their atherogenicity was only 
indirectly implied (see below). Another study by Stemme et al. 
(37) derived T cell clones from human atherosclerotic plaques 
using polyclonal mitogens as stimuli and found that these T 
cell clones responded to oxLDL in proliferative responses 
and secretion of cytokines. The specific peptides of oxLDL 
that stimulated the clones were not elucidated. In our case, 
the adoptive transfer of P6-primed T cells and P6-specific T 
cell clones in Figures  3 and 4, respectively, clearly correlates 
these cells with the exacerbation of atherosclerotic develop-
ment. The availability of the P6-specific T cell clones is an 
advance that will allow further understanding of the nature 
of the atherogenic T cells and the mechanisms of how they 
are triggered. In addition, the feeding of HFD in combination 
with immunization with P6 also greatly speed up the develop-
ment of full-blown atherosclerosis to 10 weeks rather than the 
conventional 25–30  weeks by HFD alone.
Our approach to elucidate the antigenic peptides of ApoB-100 
that bind to and stimulate peptide-specific T cells, as a means to 
identify and isolate atherogenic T cells, was based on the work 
of Liu et al. (26). The Kappler and Marrack laboratory analyzed 
the binding properties of 64 peptide sequences to murine I-Ab 
and derived a set of I-Ab-binding motifs, which predict the pos-
sible MHC-binding anchor residues and hence the sequences of 
peptides that have the physical and chemical properties of fitting 
into the antigen-binding cleft of I-Ab. Since Apoe−/− mice are also 
of the H-2b haplotype, their analysis provided us a unique oppor-
tunity to identify possible atherogenic peptides of mApoB-100. 
Subsequently, the observation that P6, but not P3, is atherogenic, 
even though both peptides can induce strong T cell proliferative 
responses (Table 1), is interesting. This investigation is ongoing.
Previous work studying ApoB-100 peptides came from 
Nilsson and co-workers. P210 (peptide 210) is one of over 
100 hApoB-100 peptides initially identified through their rec-
ognition by circulating autoantibodies found in patients with 
atherosclerotic lesions (38, 39). It was found that the presence 
of high concentrations of circulating autoantibodies specific for 
P210 corresponded to less risk of atherosclerosis development 
and vice versa. In animals immunized with ApoB-100 peptides, 
atherosclerosis was reduced by 40% (40). The mechanisms of 
how immunization with P210 results in atheroprotection, how-
ever, are not fully elucidated. CD8+ T cells, Th2, and Tregs are 
all implicated in the process (41–43). It must be pointed out that 
there are differences in the use of P210 verses P6. First, P210 was 
identified through binding to autoantibodies and is supposed 
to be a B-cell epitope of ApoB-100. On the other hand, P6 was 
identified based on I-Ab-binding motifs to T cells and is sup-
posed to be a T cell epitope. Second, immunization with P210 
requires conjugation to a carrier BSA and is injected with the 
adjuvant alum (aluminum hydroxide) (40). For P6, the peptide is 
emulsified directly with the adjuvant CFA. Alum and incomplete 
Freund’s adjuvant are known to induce suppressive Th2 and Treg 
responses (44, 45), while CFA tends to induce inflammatory 
Th1 responses (46). Overall, it seems that the mechanisms of 
atheroprotection are more complex than anticipated. On the 
other hand, by first understanding the basis of the atherogenicity 
of P6, we expect that the process of identifying antigen-specific 
therapeutic targets for atherosclerosis can be more direct. We 
are also mindful that P6 is only one of the 18 ApoB-100 peptides 
screened by the I-Ab-binding motif approach. There may be 
other atherogenic determinants affecting the development of 
atherosclerosis.
This study also uniquely identifies P6 as a physiologic 
product of antigen processing. In mice immunized with 
ApoB-100, the protein is processed by APC into a set of 
peptides to be presented to T cells. T cells with appropriate 
TCRs specific for some immunogenic peptides undergo clonal 
expansion and increase in frequencies to detectable levels. The 
observation that P6 was able to stimulate a T cell prolifera-
tive response in lymph node cells from ApoB-100-immunized 
mice, but not MOG35–55-immunized mice (Table 3), indicated 
that P6-responsive T cells were among those T cells that 
had expanded. We conclude that in the pool of naturally 
processed peptides of Apo-B100, one must be identical to or 
cross-reactive with P6. Indeed, this conclusion is supported 
by the work of Wolf et al. (manuscript submitted) in separate 
experiments using P6/I-Ab multimers to track P6-specific T 
cells showing that at 4 weeks old, Apoe−/− mice already harbored 
a high frequency of P6-specific T cells in their mesenteric 
lymph nodes.
The current study lends credence to the concept that 
atherosclerosis is an autoimmune disease, although the initial 
proposal for autoimmune atherosclerosis used HSP60 as the 
model (47, 48). With the identification of P6 as a self-T cell 
epitope, and the demonstration of P6-specific T cells as direct 
cause of exacerbating atherosclerosis, the two basic criteria for 
the definition of an autoimmune disease are corroborated. In 
this scenario, we note that the mere presence of atherogenic 
P6-specific T cells does not lead to induction of atherosclerosis; 
but in the event of a local inflammation, these cells would 
act to aggravate the inflammatory condition, resulting in 
exacerbation of the atherosclerotic lesions (Figure  4). We 
attribute these results to the need of the immune system to 
break tolerance to a self-antigen, and inflammation provides 
the stimuli for higher expression of co-stimulatory molecules to 
facilitate antigen presentation. These results are also consistent 
with the correlation that patients with autoimmune diseases 
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tend to have a higher risk of also developing cardiovascular 
disease (49).
Collectively, the identification of a T cell atherogenic epitope 
of ApoB-100 opens up new avenues whereby the mechanism of T 
cell functions in the development of atherosclerosis can be more 
closely studied. For example, the availability of P6/I-Ab tetramers 
already helped demonstrate the presence of P6-specific T cells 
in normal 4-week-old Apoe−/− mice (Wolf et  al., manuscript 
submitted). In addition, it is also anticipated that the construc-
tion of a P6-specific TCR transgenic mouse can be used to study 
the ontology and the evolution of T cell atherogenesis. More 
importantly, attempts can be made to reprogram the pathologic 
P6-specific T cell clones into induced pluripotent stem cells (50, 
51), to be followed by their redifferentiation into functional 
Tregs maintaining the same P6 specificity. This type of individu-
alized adoptive immunotherapy should be favored over global 
inhibition of the immune system as a means to treat autoimmune 
diseases (52, 53).
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